Eyemax™ IOL: a new approach to macular disease

Session Details

Session Title: Cataract Surgery Special Cases

Session Date/Time: Monday 12/09/2016 | 08:00-10:30

Paper Time: 08:44

Venue: Auditorium C6

First Author: : F.Badala ITALY

Co Author(s): :                        

Abstract Details

Purpose:

To determine safety and efficacy of a new intraocular implant, iolAMD Eyemax™, (London Eye Hospital Pharma, London, UK) in cataract patients with dry and stable wet age-related macular degeneration.

Setting:

Private Research Institute

Methods:

A prospective case series of 11 eyes (7 patients) who underwent standard phacoemulsification with Eyemax IOL implantation and have at least 3 months follow up. Outcomes were: visual acuity, intra- and postoperative complications.

Results:

Visual Acuity improved significantly in all patients, for both distance and near. All patients were left intentionally hyperopic to get additional magnification from spectacle correction. No intra or post-operative complications were recorded

Conclusions:

The Eyemax IOL implant shows promising results in improving vision in eyes with cataract and intermediate or advanced macular degeneration. Further studies are needed to confirm these preliminary results

Financial Disclosure:

NONE